TG Therapeutics (NASDAQ:TGTX)‘s stock had its “buy” rating reissued by research analysts at Cantor Fitzgerald in a report issued on Monday, AnalystRatings.com reports. They presently have a $17.00 target price on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price suggests a potential upside of 124.87% from the stock’s current price.
The analysts wrote, “: We reiterate our Overweight and $17 PT. On the 1Q call, TG discussed recent pipeline progress, including the interim data for umbralisib in marginal zone lymphoma (MZL) that were presented at AACR last month and potential updates over the rest of 2019 and early 2020. After positive interim data for umbralisib in MZL, another major milestone will be discussing recent positive MZL data with the FDA. The final MZL data are to be presented toward the end of 2019 (we think potentially at the meantime, the company plans to present an update at ASCO and meet with the FDA to discuss accelerated approval.””
Several other analysts also recently issued reports on the company. BidaskClub downgraded TG Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, April 16th. HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of TG Therapeutics in a research note on Friday, April 12th. Zacks Investment Research downgraded TG Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, April 6th. ValuEngine raised TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, March 29th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $8.00 price target on shares of TG Therapeutics in a research note on Wednesday, February 6th. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $14.07.
TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings data on Friday, May 10th. The biopharmaceutical company reported ($0.43) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.44) by $0.01. TG Therapeutics had a negative return on equity of 245.97% and a negative net margin of 98,576.14%. The business had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.04 million. Equities research analysts predict that TG Therapeutics will post -1.63 earnings per share for the current year.
Several institutional investors and hedge funds have recently added to or reduced their stakes in TGTX. Forbes J M & Co. LLP acquired a new stake in shares of TG Therapeutics in the 4th quarter valued at about $44,000. LPL Financial LLC bought a new position in shares of TG Therapeutics in the 4th quarter valued at about $49,000. NumerixS Investment Technologies Inc bought a new position in shares of TG Therapeutics in the 4th quarter valued at about $50,000. National Asset Management Inc. bought a new position in shares of TG Therapeutics in the 4th quarter valued at about $58,000. Finally, Stifel Financial Corp bought a new position in shares of TG Therapeutics in the 4th quarter valued at about $59,000. 55.19% of the stock is currently owned by hedge funds and other institutional investors.
About TG Therapeutics
TG Therapeutics, Inc, a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS). It develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing.
Featured Story: How much can an individual set aside as a catch-up contribution?
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.